A wholly owned subsidiary of a large health system engages in strategic investments across a wide variety of sectors to benefit the health system. The firm invests at a set pace with ~2 surgery centers being invested in per year and are currently looking to diversify their portfolio. The firm tends to invest in seed and pre-revenue rounds as their allocation size is on the smaller side, but is interested in revenue generating opportunities with smaller rounds. The firm is currently in the process of diversifying their portfolio and prefers investing in companies that are related to the health system in some way, companies that have done clinical studies within the health system, etc.

The firm is particularly interested in technologies that can help them increase the quality of care, decrease the cost of care, and increase the access of services to populations which have been historically denied. Beyond that though, the firm is rather opportunistic within the digital health, medical devices, healthcare services, and care delivery spaces and currently has no specific focus.

The firm requires that companies have some sort of relationship with the firm or have the endorsement of the senior management of the health system.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A PE firm based in China manages 2 active funds that focus on investments in the life science space. Their RMB fund invests $5-40 M in companies based in China, and their USD invests $5-10 M in companies of all parts of the world, with a focus in USA and China. With these funds, the firm will make investments in companies that have market opportunities in China. The firm will provide companies with resources and expertise for competitive market entry and will assist pre-market products with commercialization.

The firm is opportunistic and is open to all life science sectors in all indications, including therapeutics, medical technology, diagnostics, and digital health. In therapeutics, the firm will consider products that are in Phase II clinical trials and beyond, but may consider companies with pre-clinical or early clinical assets if they demonstrate high potential. In the medical technology sector, the firm will support devices of all regulatory pathways and will also assist with CFDA regulatory filing and approval. These devices are expected to be undergoing pivotal trials at the earliest, and should be close to commercialization.

The firm will invest only in companies that are looking to enter the market in China, and is willing to both lead and co-invest. The companies will ideally have an IPO or trade sale runway of 6 to 24 months. Companies should be backed by an experienced management team but for companies based in China, the firm can assist with the assembly of a complete management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA makes initial investments from $5-$15M with $35M over the lifetime of the company. The firm invests globally and has particular experience with partners located in the USA and Western Europe.

The firm seeks early-stage nanotechnology and stem cell research, particularly in cancer, therapeutic and regenerative medicine. The firm is primarily interested in clinical stage Ph I/II technology. The firm focuses their expertise in regenerative and therapeutic medicine, with a focus on stem cell biology, immunology, oncology, and nanotechnology to identify opportunities in the treatment of a broad range of diseases. Specific to oncology, the firm is interested in novel cancer therapies, immunotherapy, new chemotherapies, targeted therapy, management of adverse consequences, and quality of life improvement.

The firm requires management teams with experience in the field. The firm seeks board representation post-investment and remains actively supportive with portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in the USA and Western Europe currently manages two funds, and typically makes equity investment into early-stage life science companies. The typical investment size ranges from €0.5million-€8million ($0.7million-$10million). The second fund looks to make 10 to 15 investments. The firm generally invests in companies based in the US and Europe.

The firm is currently looking for new investment opportunities in the life science space. The firm focuses on Therapeutics, Diagnostics and Medical Devices sectors. The firm is very opportunistic in terms of subsectors and indications, and it is most interested in companies in pre-clinical and clinical stages. In the past, the firm was active in therapeutics companies targeting drug delivery and gene therapy. The firm was also active in device companies developing single use cardiovascular devices and implantable devices.

The firm primarily invests in private companies with experienced management teams, but it will also consider public companies, depending on the opportunity. The firm seeks to take a board seat in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm that currently manages 2 funds makes equity and mezzanine investments into venture stage companies in the life science space ranging from $1 -10 million over the lifetime of the investment. The firm has a geographical focus on companies in Western Europe plans to make 2-3 investments over the next 6-9 months.

The firm is looking for companies in the Therapeutics, Diagnostics and Medical Technology spaces. While the firm considers all subsectors and indications, including orphan indications, they are especially interested in the vaccine field. The firm generally looks for companies that have proof of concept from animal studies generally investing in Series A rounds. The firm is very open to repurposed and reformulations and they generally only consider investment into biosimilars when a strong case for a high value inflection point can be made.

The firm looks for experienced management teams and generally looks to take a board seat. The firm often leads or co-leads investment rounds always looking to take an active role in the development of its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A biotech sector fund with headquarters in China is equipped with state-of-the-art instruments housed by modern laboratories in an artistically designed building. The firm works with top ten largest global pharmaceutical companies and small to medium sized US and Europe-based businesses in studies of gene-to-structure, in vitro and in vivo assays, target ID, ADME, animal models, and more.

The firm can allocate from $200,000 to $800,000 of equity capital in seed round companies and can make investments ranging from $1 to $10 million in series A companies. The firm looks to tailor its incubator and CRO services to the needs of its partners, helping them to reach key value-added milestones. The firm will consider opportunities based in China and North America, companies within a strong China angle involvement is their sweet spot. The firm is actively seeking in-licensing opportunities and plans to make 10-12 investments next year but is flexible.

The firm focuses mostly on therapeutics, while the firm is also open to Diagnostics. The firm can utilize its CRO services to advance portfolio company’s products into or through clinical trials. The firm is currently most interested in small molecule first-in-class drugs. The firm is opportunistic in terms of subsector and indication. For therapeutics, the firm is open to invest from super early-stage to pre-clinical stage. The firm will not invest in Medical Devices or Digital Health companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A US fund invests in early-stage startups in many industries with a preference for healthcare and IT technology. Typical equity investment size ranges from US$0.5-2 million in Pre-A to Series A stage companies. The firm is open to either leading or following in a syndicated round. The firm expects to make 10+ deals in the next 12 months and can invest globally with a focus on the US and Canada.

The firm considers broadly across healthcare industries including innovative drugs, medical devices, diagnostics, and digital health products. The firm has an increased interest in medical devices and imaging technology. The firm prefers companies that develop disruptive technologies to solve unmet medical needs.

The firm is looking for experienced management teams. The firm can leverage its innovation center in China to assist with commercialization in the China market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.